https://www.thepharmaletter.com/pharma-news/pfizer-gains-as-dacomitinib-follows-in-footsteps-of-lorlatinib
Pfizer gains as dacomitinib follows in footsteps of lorlatinib | Pharmaceutical | The Pharmaletter
Dacomitinib took a step towards becoming a new treatment option in locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) on Wednesday.
pfizergainsdacomitinibfollowsfootsteps
https://www.medicalhalo.com/en/oncology/1170.html
Common side effects of dacomitinib_Medicalhalo
common side effectsdacomitinib
https://www.cgtlive.com/view/dacomitinib-tops-gefitinib-first-line-egfr-mutant-nsclc
Dacomitinib Tops Gefitinib in First-Line EGFR-Mutant NSCLC | CGTlive®
Oct 16, 2026 - The second-generation EGFR tyrosine kinase inhibitor dacomitinib significantly improved progression-free survival over gefitinib as a first-line therapy for...
in firstdacomitinibtopsgefitinibline